- $938.34m
- $895.51m
- $81.39m
MeiraGTx Holdings PLC reports results for the quarter ended in September - Earnings Summary
MeiraGTx Holdings PLC expected to post a loss of 58 cents a share - Earnings Preview
Brief: MeiraGTx Says Treatment With Botaretigene Sparoparvovec Was Found To Have An Acceptable Safety Profile In Phase 1/2 Study
Brief: Meiragtx Reports Second Quarter 2022 Financial And Operational Results
Brief: MeiraGTx Announces Financing Agreement With Perceptive Advisors For Up To $100 Million
Brief: Meiragtx Announces Positive Top-Line Data From The Mgt009 Phase 1/2 Clinical Study Demonstrating Safety And Improvement In Multiple Domains Of Vision In X-Linked Retinitis Pigmentosa Patients Treated With Botaretigene Sparoparvovec (Aav-Rpgr) Compared To Untreated Randomized Control
MeiraGTx Holdings PLC reports results for the quarter ended in March - Earnings Summary
Brief: MeiraGTx Reports Q1 Loss Per Share Of $0.70
MeiraGTx Holdings PLC expected to post a loss of 52 cents a share - Earnings Preview
MeiraGTx Holdings PLC reports results for the quarter ended in December - Earnings Summary
Brief: Meiragtx Reports Fourth Quarter And Full Year 2021 Financial And Operational Results
MeiraGTx Holdings PLC expected to post a loss of 51 cents a share - Earnings Preview
Brief: Meiragtx Receives Clinical Development Milestone Payment From Janssen
MeiraGTx jumps after promising data from dry mouth therapy study
Brief: MeiraGTx Announces Positive Preliminary Data from the Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Holdings PLC reports results for the quarter ended in September - Earnings Summary
Brief: MeiraGTx Reports Q3 Basic And Diluted Net Loss Per Ordinary Share Of $0.59
MeiraGTx Holdings PLC expected to post a loss of 51 cents a share - Earnings Preview
MeiraGTx Holdings PLC reports results for the quarter ended in June - Earnings Summary